The metformin effect on survival in Middle Eastern patients (pts) with type II diabetes (DM) and colorectal cancer (CRC).

e14541 Background: Epidemiologic data suggest that anti-DM medications may impact overall survival (OS) in CRC pts who have type 2 DM. Although type 2 DM and CRC are major health problems in the Middle East, little data exist on pts with both conditions from this region. Methods: Medical records from 1,898 CRC pts seen at King Hussein Cancer Center, between 1/1/2004 and 12/31/2012 were evaluated for prevalence of type 2 DM; those with both conditions were evaluated for anti-diabetic therapy and treatment outcomes (OS and progression-free survival (PFS)). Results: 355 type 2 DM CRC patients were identified (prevalence 18.7%); 25 pts were censored as their anti-DM medications were not known. Median age of 355 pts analyzed was 62 years (36-88), Male: Female ratio 1.5:1, non-metformin (n = 140, 42%), metformin only (n = 56, 17%), metformin + insulin (n = 15, 5%), metformin + another oral agent (n = 119, 36%). Metformin use increased over time (24% in 2004 to 79% in 2012). Adjusting for age, gender, body mass ...